TherapeuticsMD Cash Conversion Cycle from 2010 to 2026
| TXMD Stock | USD 2.61 0.06 2.35% |
Cash Conversion Cycle | First Reported 2010-12-31 | Previous Quarter 664.46 | Current Value 697.68 | Quarterly Volatility 1.7 K |
Check TherapeuticsMD financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TherapeuticsMD's main balance sheet or income statement drivers, such as Depreciation And Amortization of 363.7 K, Interest Expense of 10.4 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.088 or PTB Ratio of 0.34. TherapeuticsMD financial statements analysis is a perfect complement when working with TherapeuticsMD Valuation or Volatility modules.
TherapeuticsMD | Cash Conversion Cycle | Build AI portfolio with TherapeuticsMD Stock |
Latest TherapeuticsMD's Cash Conversion Cycle Growth Pattern
Below is the plot of the Cash Conversion Cycle of TherapeuticsMD over the last few years. It is TherapeuticsMD's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TherapeuticsMD's overall financial position and show how it may be relating to other accounts over time.
| Cash Conversion Cycle | 10 Years Trend |
|
Cash Conversion Cycle |
| Timeline |
TherapeuticsMD Cash Conversion Cycle Regression Statistics
| Arithmetic Mean | 281.41 | |
| Coefficient Of Variation | 604.14 | |
| Mean Deviation | 917.37 | |
| Median | (116.54) | |
| Standard Deviation | 1,700 | |
| Sample Variance | 2.9M | |
| Range | 8.6K | |
| R-Value | 0.27 | |
| Mean Square Error | 2.9M | |
| R-Squared | 0.07 | |
| Significance | 0.30 | |
| Slope | 90.29 | |
| Total Sum of Squares | 46.2M |
TherapeuticsMD Cash Conversion Cycle History
About TherapeuticsMD Financial Statements
TherapeuticsMD stakeholders use historical fundamental indicators, such as TherapeuticsMD's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although TherapeuticsMD investors may analyze each financial statement separately, they are all interrelated. For example, changes in TherapeuticsMD's assets and liabilities are reflected in the revenues and expenses on TherapeuticsMD's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in TherapeuticsMD. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash Conversion Cycle | 664.46 | 697.68 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:Check out the analysis of TherapeuticsMD Correlation against competitors. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth 0.433 | Return On Assets | Return On Equity |
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.